EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieÄquivalenzstudieMultizentrische Studie

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

Michael E Wechsler, Parameswaran Nair, Benjamin Terrier, Bastian Walz, Arnaud Bourdin, David R W Jayne iD, David J Jackson iD, Florence Roufosse, Lena Börjesson Sjö, Ying Fan, Maria Jison, Christopher McCrae und 5 weitere

New England Journal of Medicine · 07.03.2024 · 390 (10) · 911-921

DOI: 10.1056/nejmoa2311155 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 07.03.2024. Verfasst von Michael E Wechsler und 16 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Medicine, National Jewish Health, Denver (M.E.W.); McMaster University and St. Joseph's Healthcare, Hamilton, ON, Canada (P.N.…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Churg-Strauss Syndrome, Anti-Inflammatory Agents, Interleukin-5 Receptor alpha Subunit. Die Arbeit wurde bisher 251-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedChurg-Strauss SyndromeAnti-Inflammatory AgentsInterleukin-5 Receptor alpha SubunitAdultHumansChronic DiseaseGlucocorticoidsGranulomatosis with PolyangiitisRecurrenceDouble-Blind MethodRemission InductionInjections, SubcutaneousEosinophils

Substanzen

Antibodies, Monoclonal, HumanizedbenralizumabGlucocorticoidsmepolizumabAnti-Inflammatory AgentsIL5RA protein, humanInterleukin-5 Receptor alpha Subunit

Autor:innen und Institutionen

  • From the Department of Medicine, National Jewish Health, Denver (M.E.W.); McMaster University and St. Joseph's Healthcare, Hamilton, ON, Canada (P.N.); the Department of Internal Medicine, National Referral Center for R…

ORCID-Profile: David R W Jayne, David J Jackson

Förderung

  • AstraZeneca

Zitieren

APA

Wechsler, M. E., Nair, P., Terrier, B., Walz, B., Bourdin, A., Jayne, D. R. W., Jackson, D. J., Roufosse, F., Börjesson Sjö, L., Fan, Y., Jison, M., McCrae, C., Necander, S., Shavit, A., Walton, C., Merkel, P. A., & MANDARA Study Group (2024). Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine, 390(10), 911-921. https://doi.org/10.1056/nejmoa2311155

Vancouver

Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, et al. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine. 2024;390(10):911-921. doi:10.1056/nejmoa2311155

BibTeX
@article{Wechsler2024,
  author = {Wechsler, Michael E and Nair, Parameswaran and Terrier, Benjamin and Walz, Bastian and Bourdin, Arnaud and Jayne, David R W and Jackson, David J and Roufosse, Florence and Börjesson Sjö, Lena and Fan, Ying and Jison, Maria and McCrae, Christopher and Necander, Sofia and Shavit, Anat and Walton, Claire and Merkel, Peter A and MANDARA Study Group, MANDARA Study Group},
  title = {Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {390},
  number = {10},
  pages = {911--921},
  doi = {10.1056/nejmoa2311155}
}
Kostenlos starten →